A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Public ClinicalTrials.gov record NCT02091999. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Study identification
- NCT ID
- NCT02091999
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 213 participants
Conditions and interventions
Interventions
- enfortumab vedotin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 13, 2014
- Primary completion
- Dec 6, 2022
- Completion
- Dec 6, 2022
- Last update posted
- Oct 31, 2024
2014 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site US00012 | Los Angeles | California | 90033 | — |
| Site US00019 | Stanford | California | 94305 | — |
| Site US00017 | Aurora | Colorado | 80045 | — |
| Site US00006 | New Haven | Connecticut | 06520 | — |
| Site US00007 | Miami | Florida | 33136 | — |
| Site US00008 | Tampa | Florida | 33612 | — |
| Site US00004 | Fairway | Kansas | 66205 | — |
| Site US00005 | Ann Arbor | Michigan | 48109 | — |
| Site US00003 | Detroit | Michigan | 48201 | — |
| Site US00021 | Las Vegas | Nevada | 89119 | — |
| Site US00018 | New York | New York | 10029 | — |
| Site US00002 | New York | New York | 10065 | — |
| Site US00023 | Chapel Hill | North Carolina | 27599 | — |
| Site US00013 | Philadelphia | Pennsylvania | 19111 | — |
| Site US00020 | Pittsburgh | Pennsylvania | 15232 | — |
| Site US00024 | Fairfax | Virginia | 22031 | — |
| Site US00009 | Madison | Wisconsin | 53792 | — |
| Site US00015 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02091999, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2024 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02091999 live on ClinicalTrials.gov.